Send to

Choose Destination
Anticancer Drug Des. 1999 Apr;14(2):93-106.

Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.

Author information

Laboratoire de Pharmacognosie, URA CNRS 1310, Université Paris V, France.


New prodrugs consisting of a beta-D-glucuronic acid linked to a MDR reversal agent (verapamil, quinine or dipyridamole) through a self-immolative spacer were synthesized. Four of them were selected for their reduced cytoxicity and beta-glucuronidase enzymatic efficient hydrolysis. Combined use of these prodrugs with a beta-D-glucuronyl-spacer-doxorubicin (HMR1826) according to an ADEPT strategy restored in vitro the sensibility of a MDR resistant strain.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center